An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces grant of nonqualified stock options to new employee, part of inducement to join, with exercise price of $1.83 and vesting over four years.
Positive
The grant of nonqualified stock options demonstrates Gritstone's commitment to attracting and retaining top talent, which could positively impact the company's future performance.
Negative
None.
EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 4,600 shares of its common stock with an exercise price of $1.83, which is equal to the closing price of Gritstone’s common stock on November 2, 2023, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees’ date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees’ continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone’s 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
About Gritstone bio Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone bio Contacts Investors: George E. MacDougall Gritstone bio, Inc. ir@gritstone.com
What is the announcement from Gritstone bio, Inc. (Nasdaq: GRTS)?
Gritstone bio, Inc. (Nasdaq: GRTS) announced the granting of nonqualified stock options to a new employee as part of an inducement to join the company.
How many shares of common stock can the employee purchase with the stock options?
The employee can purchase an aggregate of 4,600 shares of Gritstone's common stock.
What is the exercise price of the stock options?
The exercise price of the stock options is $1.83, which is equal to the closing price of Gritstone's common stock on November 2, 2023.
How long will it take for the stock options to vest?
The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter.
What are the conditions for vesting the stock options?
The options vesting is subject to the employees' continued employment with Gritstone on the vesting dates, as per the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
